'Defeating the dragon' - can we afford not to treat patients with heroin dependence?

South African Journal of Psychiatry

Volumn 16, Issue 3, 2010, Pages 75-79

  Weich, Lize ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; METHADONE; NALOXONE; NALTREXONE; OPIATE;

ABSTINENCE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG COST; DRUG DETOXIFICATION; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG WITHDRAWAL; EMPLOYMENT; HELP SEEKING BEHAVIOR; HUMAN; LIFESTYLE; MAINTENANCE THERAPY; MOTOR DYSFUNCTION; OPIATE ADDICTION; PATIENT CARE; PATIENT COMPLIANCE; PUBLIC HEALTH; QUALITY OF LIFE; RELAPSE; SOUTH AFRICA; SUBSTITUTION THERAPY; TREATMENT OUTCOME; WELLBEING;

EID: 78449246538     PISSN: 16089685     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajpsychiatry.v16i3.260     Document Type: Article

References (35)

1. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 2002;1(1):13-20.
2. United Nations Office for Drugs and Crime. 2007 World Drug Report. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2007.html (accessed 14 September 2010).
3. Plüddemann A, Dada S, Parry C, et al. Monitoring alcohol & drug abuse trends in southern Africa (July 1996 - June 2009). Phase 26 SACENDU research brief 2009;12(2). http://www.sahealthinfo.org/admodule/sacendu.htm (accessed 14 September 2010).
4. Plüddemann A, Parry C, Jordaan E, Flisher A. The nature and extent of heroin use in Cape Town. http://www.sahealthinfo.org/admodule/reportheroinphase2.pdf (accessed 14 September 2010).
5. Plüddemann A, Pary C, Flisher A, Jordaan E. Heroin users in Cape Town, South Africa: injection practices, HIV-related risk behaviors and other health consequences. J Psychoactive Drugs 2008;40(3):273-279.
6. Rounsaville B, Weissman M, Kleber H, Wilber C. Hetrogeity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982;39:161-166.
7. Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from illicit opiates. Addiction 1999;94:221-229.
8. WHO/UNODC/UNAIDS position paper. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. http://www.unodc.org/docs/treatment/Brochure_E.pdf (accessed 14 September 2010).
9. Gossop M, Stewart D, Browne N, Marsden J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002;97:1259-1267.
10. Price RK, Risk NK, Spitznagel EL. Remission from drug abuse over a 25-year period: Patterns of remission and treatment use. Am J Public Health 2001;91:1107-1113.
11. Weich L, Perkel C, Van Zyl N, Rataemane ST, Naidoo L. Medical management of opioid dependence in South Africa. S Afr Med J 2008;98(4):280-283.
12. Minozzi S, Amato L, Vechi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006; Jan 25: (1) CD 001333.
13. Gossop M, Marsden J, Stewart D, Lehmann P, Strang J. Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. Br J Gen Pract 1999;49:31-34.
14. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993;119:23-27.
15. Bates M, Pemberton DA. The effects of methadone prescribing in a clinic setting on the criminal activity of drug users. Scott Med J 1996;41:173-175.
16. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996;16:58-67.
17. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981;7:249-256.
18. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988;30:673-684.
19. Dole VP, Joseph H. Long-term outcome of patients treated with methadone maintenance. Ann NY Acad Sci 1978;311:181-189.
20. Fairbank JA, Dunteman GH, Condelli WS. Do methadone patients substitute other drugs for heroin? Predicting substance use at 1-year follow-up. Am J Drug Alcohol Abuse 1993;19:465-474.
21. Caplehorn JR Dalton MS, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 1994;89:203-209.
22. Sees, KL Delucchi KL, Masson C, et al. Methadone maintenance vs. 180 day psychosocially enriched detoxification for the treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283:1303-1310.
23. Herget, G. Methadone and buprenorphine added to the WHO list of essential medications. HIV AIDS Policy Law Rev 205;10:23-24.
24. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965;193:646-650.
25. Krantz MJ, Mehler PS. QT Prolongation: methadone's efficacy-safety paradox. Lancet 2006;368:556-557.
26. Dumm JE. Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonist and antagonist actions. Br J Pharmacol 1981;74:627-633.
27. Reynaud M, Tracqui A, Petit G, Potard D, Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry 1998;155:448-449.
28. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 1978;35:501-516.
29. O'Connor JJ, Moloney E, Travis R, Cambell A. Buprenorphine abuse among opiate addicts. Br J Addict 1988;83:1085-1087.
30. Mendelson J, Jones RJ, Clinical and pharmacological evaluation of buprenporphine and naloxone combinations: why the 4:1 ratio for treatment? Drug and Alcohol Dependence 2003;70:S29-S37.
31. Bell J, Shanahan M, Mutch C, et al. A randomised trial of effectiveness and costeffectiveness of observed versus unobserved administration of buprenorhine-naloxone for heroin dependence. Addiction 2007;102:1899-1907.
32. Simpson DD, Joe GW, Brown BS. Treatment retention and follow-up outcomes in Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997;11:294-307.
33. Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 years follow-up results. Addiction 2003;98:291-303.
34. Teeson M, Mills K, Ross J, Darke S, Williamson A, Harvard A. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2008;103:80-88.
35. Lintzeris N. Maximising access: a tale of morality, politics and pharmacology. Presented at the Improving Outcomes in the Treatment of Opioid Dependence conference, 21 - 23 April 2009, Cannes, France.